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SPECIFIC AIMS
The central cause of Alzheimer's disease (AD) is widely believed to be the aggregation of amyloid proteins (mainly A␤1-42); thus small, peptide-based aggregation inhibitor molecules [␤-sheet-breakers (BSBs)] may represent a promising, novel treatment of the disease. Here we investigated the biological effects of an endogenous tetrapeptide, endomorphin-2 (YPFF, End-2), the structure of which shows high similarity to Leu-Pro-PhePhe-Asp (LPFFD), a well-known BSB peptide, on the A␤1-42 induced biological effects and on the aggregation process by using transmission electron microscopy (TEM), quasielastic light-scattering (QLS), tritium labeled End-2 binding assay, circular dichroism (CD), a cell-viability assay, and in vitro and in vivo electrophysiology.
PRINCIPAL FINDINGS

End-2 binds to A␤ but does not interfere with the aggregation of A␤1-42
Experiments were carried out by using A␤1-42, LPFFD, and End-2 synthesized in house. For the TEM experiments, 10 Ϫ4 M A␤1-42 containing solutions were incubated for 5 days either alone or with 5 ϫ 10 Ϫ4 M End-2. Electromicrographs were made immediately after dissolving A␤1-42 (0 h) and after incubation periods of 1 and 5 days. A few protofibrils and spherical oligomers could be observed at day 0 in either solution (Fig. 1, A and B, top) . After 1 day of incubation, both samples contained long, mature, smooth amyloid fibrils emanating from the seeding centers without any observable difference between the two time-matched different samples (Fig. 1, A and B,  middle) . Although, after 5 days of incubation period, the concentration of fibrils increased further, the End-2 containing solution resembled the control one. Our observations by electron microscopy indicate that the tetrapeptide did not affect the fibrillogenesis of A␤1-42 ( Fig. 1, A and B, bottom) . Binding assay carried out with tritium labeled End-2 showed that the tetrapeptide binds to aggregated A␤1-42 in a reversible manner. The particle size distribution of A␤ and End-2 containing solution did not differ from that of A␤ alone after 48 h, as revealed by QLS. In contrast, LPFFD shifted the distribution toward oligomers and dimers. CD measurements proved that End-2 and A␤1-42 forms a complex in the initial state of the aggregation process, although the aggregation kinetics remained unchanged.
End-2 reduces the neurotoxicity of A␤1-42 in a cell-viability assay
We investigated whether End-2 protects against A␤1-42 induced neurotoxicity by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) cell viability assay on differentiated SH-SY5Y cells. Because End-2 acts on -opioid receptor, a synthetic peptide agonist of the same receptor, [d-Ala (2) , N-Me-Phe (4), Gly (5)-ol]-enkephalin (DAMGO), was used as control substance. Data were analyzed by using ANOVA with post hoc Bonferroni test.
Both End-2 and DAMGO were applied in 1, 10, 100, and 200 M, either alone or in a mixture with 10 Ϫ5 M A␤1-42. Application of 10 Ϫ5 M A␤1-42 resulted in a decrease of cell viability. Reduction of MTT into formazan in the SH-SY5Y cell line decreased to 58 Ϯ 8% (nϭ21), as described previously. DAMGO, applied in gradually increasing concentrations, was unable to interfere with A␤1-42 induced decrease of MTT reduction. In contrast, End-2 could significantly attenuate the inhibition of MTT reduction of A␤1-42 in a dose-dependent manner. The effect was significant, when the tetrapeptide was applied in 100 and in 200 M concentration with 10 -5 M A␤1-42 (77Ϯ7 and 79Ϯ10%, respectively, PϽ0.01, nϭ21). DAMGO and End-2 did not affect cell viability alone at the concentrations used.
End-2 prevents the A␤1-42 induced field excitatory postsynaptic potential attenuation in vitro
Coronal brain slices from the primary motor cortices of 20-to 30-day-old Wistar rats were placed in a recording chamber and were perfused continuously with artificial cerebrospinal fluid. The amplitude of the initial negative component of the field excitatory postsynaptic potential (fEPSP) evoked by stimuli applied through horizontally displaced electrodes in layers II/III was recorded. Statistical significance was determined by means of Student's t test. The applied 10 Ϫ5 M A␤1-42 decreased the amplitude to 58.9 Ϯ 10% (PϽ0.05, nϭ15), while End-2 successfully prevented the attenuation (92.8Ϯ16%, nϭ6). In contrast, application of A␤1-42 and DAMGO containing mixture (1:5 M) resulted in significant fEPSP amplitude attenuation (57Ϯ14%, nϭ8, PϽ0.05). End-2 and DAMGO in a concentration of 5 ϫ 10 Ϫ5 M did not alter the measured fEPSPs (100.3Ϯ17.6%, nϭ13 and 91.7Ϯ11.4%, nϭ14, respectively).
End-2 protects against the hyperexcitability caused by A␤1-42 in vivo
NMDA-evoked neuronal firing was registered from the CA1 region of Wistar rats weighting 300 -360 g by means of extracellular single-unit recordings combined with microiontophoresis. NMDA was ejected every minute; the statistical evaluations were performed by using the total number of spikes evoked during each epoch of excitation. To elucidate the mechanism of protection of End-2, two kinds of application were used: 1) ejection of A␤1-42 and End-2 or A␤1-42 and DAMGO containing mixture (5ϫ10 Ϫ5 M and 2.5ϫ10 Ϫ4 M, respectively), and 2) ejection of 2.5 ϫ 10 Ϫ4 M End-2/DAMGO right before 5 ϫ 10 Ϫ5 M A␤1-42 application (coiontophoresis; Fig. 2 ).
A␤1-42 ejection alone induced a massive enhancement of neuronal excitability (269Ϯ16%; PϽ0.05; nϭ14). The coiontophoretic application of End-2 and A␤1-42 resulted in a similar increase of firing (348Ϯ65%, PϽ0.05; nϭ7). In contrast, ejection of A␤1-42 and End-2 containing solution did not increase the NMDA-evoked responses (115Ϯ21%, nϭ6). DAMGO applied either coiontophoretically or in a mixture with A␤1-42 emerged in hyperexcitability similar to A␤1-42 induced responses (238Ϯ37%, PϽ0.05, nϭ6 and 269Ϯ37%, PϽ0.05, nϭ6, respectively). End-2 and DAMGO alone increased the NMDA-elicited neuronal firing in a less pronounced manner (162Ϯ14%, PϽ0.05, nϭ9 and 167Ϯ5%, PϽ0.05, nϭ5).
CONCLUSIONS
Our results show that an endogenous tetrapeptide, End-2, protects neurons against A␤1-42 induced effects Fig. 3 . The mechanism of protection is not mediated by the -opioid receptor. Data from TEM, QLS, binding assay, and CD measurements suggest that the tetrapeptide is capable of binding to the surface of A␤ assemblies without interfering in the kinetics of fibrilogenesis. It is widely accepted that protective substances that bind to aggregated A␤ have a BSB effect. We report for the first time that a neuroprotective, A␤1-42 binding small molecule does not arrest fibril formation. These results are in accord with the findings that brain structures with high End-2 content are unaffected both in AD patients and in transgenic animals. However, the hippocampal region and the neocortex, which do not show End-2 like immunoreactivity, are severely damaged in the disease, suggesting a possible role for the endogenous tetrapeptide in the area-selective neuronloss seen in AD. Unfortunately, approaches aimed to increase End-2 concentration in the brain presumably would not offer rational treatment of AD patients. The activation of -opioid receptors increases the net excitability in the CA1 region and may result in focal epileptic seizures. Therefore, the sequence of End-2 is what may be exploited as a lead sequence for drug development in the treatment of AD. Alzheimer's disease (AD) is the leading cause of senile dementia (1). The disease is histopathologically characterized by the deposition of a mainly 42 amino acid residue peptide (A␤1-42) in senile plaques in the brain, a massive neurite dystrophy, and neuronal loss chiefly in the basal forebrain and hippocampus (2) . The underlying cause of the disease seems to be the extracellular accumulation and aggregation of amyloid beta peptides, encoded by a gene for the much larger amyloid precursor protein (APP) (3, 4) . A␤ deposition is an invariable feature of the disease, and the heritable form of AD is mainly linked with mutations in the APP-related genes (5). Aggregated A␤1-42 has been shown to exert toxic and disruptive effect on neurons in vitro (6, 7) and in vivo (8, 9) . Impaired cellular ion homeostasis (10, 11) , Ca 2ϩ influx (12) (13) (14) , oxidative stress (15) , and NMDA receptor enhancement (16, 17) has been reported after A␤1-42 application. Additionally, hippocampal and cortical excitatory postsynaptic potential (EPSP; refs 17, 18) and long-term potentiation (LTP; ref 19) are attenuated both in vivo and in vitro by A␤1-42. The toxicity of A␤ peptides proved to correlate well with their aggregation properties (20) ; therefore, a promising approach in the treatment of AD would be the inhibition of amyloid aggregation (21) . The introduction of so called beta-sheet-breaker (BSB) peptides (22) (23) (24) allowed the design of rational, putative protective peptides. These small molecules arrest A␤ fibrillogenesis and/or amyloid neurotoxicity in vitro, but only a few compounds have been reported to be active in vivo (17) . One such compound is Leu-Pro-Phe-Phe-Asp (LPFFD), which after in vitro tests, successfully reduced amyloid load and cerebral damage in transgenic animals (25) .
A recently isolated endogenous tetrapeptide, endomorphin-2 (End-2, YPFF, Tyr-Pro-Phe-Phe; ref 26) , shows high structural similarity with LPFFD: the Cterminal tripeptide sequence (PFF) of End-2 perfectly matches with the middle tripeptide sequence of LPFFD. In addition, the high End-2 containing central nervous system (CNS) areas (27, 28) seem to be unaffected both in human AD and in transgenic animals (29 -31) . Those areas that suffer massive cell loss in AD, including the hippocampal formation and neocortex, show no or little End-2 like immunoreactivity. Therefore, it is intriguing to suppose that this endogenous tetrapeptide might have some protective action against A␤1-42.
We have used several independent methods to evaluate the putative neuroprotective effect and the mechanism of End-2 against aggregated A␤1-42. End-2 and A␤1-42 interaction was measured by tritium-labeled End-2 binding assay. Transmission electron microscopy (TEM), quasielastic light-scattering (QLS), and circular dichroism (CD) were used to elucidate whether the tetrapeptide has an antifibrillogenic effect. Neuroprotection against the cellular redox activity attenuation and neuromodulatory effects of A␤1-42 were tested by an in vitro cell viability assay and by in vitro and in vivo electrophysiology.
End-2 possesses some antioxidant effect alone (32) and protective action through the activation of the -opioid receptor (MOR; refs 33, 34); therefore, we used a synthetic peptidomimetic agonist of the same receptor, [d-Ala (2), N-Me-Phe (4), Gly (5)-ol]-enkephalin (DAMGO), as a control substance in the biological measurements. Here, we report that End-2, an endogenous tetrapeptide has a MOR-independent protective action against the neuromodulatory effects of A␤1-42 both in vitro and in vivo; however, it has no antifibrillogenic action.
MATERIALS AND METHODS
Peptide synthesis
A␤1-42 was synthesized in our laboratory by a solid-phase procedure involving the use of Wang-resin and Fmoc chemistry. The peptide was purified on a C-4 RP-HPLC column with an acetonitrile gradient; pure fractions were pooled and lyophilized. A␤1-42 used for biological experiments was repeatedly lyophilized from aqueous solution resulting in assemblies with higher aggregation rate. Purity control and proof of structure were achieved by amino acid analysis and mass spectrometry (ESI MS, FinniganMat TSQ 7000). End-2 and H-Tyr-[
were also prepared in our laboratory using End-2 containing dehydro proline in position 2 and tritium gas in the presence of Pdo/BaSO 4 . DAMGO was purchased from BACHEM (Budendorf, Switzerland).
TEM
To destroy the preformed aggregates, A␤1-42 was dissolved in HFIP and incubated for 24 h at ambient temperature. Then the organic solvent was removed in vacuo. Solutions of A␤1-42 (100 M), either alone or coincubated with 500 M End-2, were prepared by dissolving the peptide(s) in deionized water. Dissolution was promoted by constant agitation of the solution for 2 min with an automatic pipette, followed by a sonication for 10 min. To initiate and facilitate the nucleation-dependent aggregation of A␤1-42, peptide samples were seeded with a definite volume of preaggregated A␤1-42 solution (cϭ0.5 mg/ml, 10 l were added to 1 ml sample). Electron micrographs were taken from the freshly prepared peptide solutions (0 h) and after incubation for 24 and 120 h at 37°C. Ten microliter droplets of solutions were placed on 400 mesh carbon-coated copper grids (Electron Microscopy Sciences, Washington, PA), incubated for 2 min, fixed with 0.5% (v/v) glutaraldehyde solution, washed three times with deionized water, and finally stained with 2% (w/v) uranyl acetate. Specimens were studied with a Philips CM 10 transmission electron microscope (FEI Company, Hillsboro, OR) operating at 100 kV. Images were taken by a Megaview II Soft Imaging System routinely at magnifications of ϫ25,000, ϫ46,000, and ϫ64,000 and analyzed by an AnalySis 3.2 software package (Soft Imaging System, Münster, Germany).
QLS measurements
All experiments were performed at 25°C with a Malvern Zetasizer Nano ZS Instrument (Malvern Instruments, Worcestershire, UK) equipped with a He-Ne laser (633 nM), applying the Non-Invasive Back Scatter (NIBS) technology, which means detection of the scattered light at an angle of 173°. The translational diffusion coefficients were obtained from the measured autocorrelation functions using the regularization algorithm CONTIN built in the software package Dispersion Technology Software 4.0 (Malvern Instruments). With the assumption of the scattering particles as hard spheres, their apparent hydrodynamic radius can be calculated from the diffusion parameters by using the Stokes-Einstein equation R h ϭ k B T/(6D T ), in which k B is the Boltzmann constant, T is the absolute temperature, is the viscosity of the medium, and D T is the translational diffusion coefficient. Samples were prepared as given above, and the aqueous ones were filtered before incubation through a 0.45 m PVDF sterile membrane filter (Roth, Karlsruhe, Germany) to remove the possibly interfering dust particles. Correlation function and distribution of the apparent hydrodynamic radii over the scattered intensity of the samples were monitored for 2 days.
Radioactive binding assay
Twice lyophilized A␤1-42 (1.0 mg/ml) was aged in a pH 7.4 buffer [Tris (56 mM), NaCl (112 mM), EGTA (1.12 mM), and MgCl 2 (3.36 mM)] for a week. A␤1-42 suspension was diluted to 0.2 mg/ml before use. The assays were performed in 96-well plates in which the wells contained 0.01 mg/ml A␤1-42; 8 ϫ 10 Ϫ8 [ 3 H]End-2 and different concentrations of nonlabeled End-2. After 60 min incubation at room temperature, the content of the plate was transferred to a Multiscreen HTS filtration plate (Millipore Corporation, Bedford, MA). After filtration, the wells were washed four times with 200 l buffer and dried, and 75 l scintillation cocktail (OptiPhase Supermix, Perkin-Elmer) were added into each well. Radioactivity was measured in a scintillation counter. Experiments were performed in duplicates.
CD measurements
CD measurements were performed at 25°C on a Jobin-Yvon Mark VI dichrograph using a 1 mm pathlength quartz cuvette. All spectra were the average of four scans, the resolution was 0.2 nM. A␤1-42 peptide was dissolved in tridistilled water (pH Ϸ5) at a concentration of 0.2 mg/ml (44 M) and sonicated for 5 min. After sonication, the samples were immediately measured (0 h) and then after 1, 3, 6, 24, and 48 h. The samples were incubated during the aging period at 25°C. The band intensities were expressed as mean residue ellipticity, [⌰] MR , and given in units of deg ⅐ cm Ϫ2 ⅐ dmol Ϫ1 using a mean residual wt 114.
3-(4,5-Dimethylthiazolyl-2)-2,-5-diphenyltetrazolium bromide assay for cell viability
The standard method of (3-(4,5-dimethylthiazolyl-2)-2,-5-diphenyltetrazolium bromide) (MTT) assay modified by Datki et al. (7) was used to measure the effect of End-2 and DAMGO against A␤1-42 in a dose-dependent manner, using differentiated SH-SY5Y cells. Cells were incubated with the following peptides: 1) 10 M aggregated A␤1-42; 2) 1, 10, 100, and 200 M End-2/DAMGO; and 3) a mixture of 10 M aggregated A␤1-42 and 1, 10, 100, and 200 M End-2/ DAMGO in a 24-well plate for 24 h. One-hundred milliliters of MTT stock solution (4 mg/ml) were added to each well, containing Ϸ1 ml medium, and the mixture was incubated for 3 h. The MTT solution was carefully decanted off, and formazan was extracted from the cells with 1 ml of a DMSO/ EtOH (4:1) mixture in each well. The formazan color intensity was measured with a 96-well ELISA plate reader at 550 nM with the reference filter set to 620 nM. Experiments were done in triplicates, with seven measurements within each trial (nϭ21).
In vitro electrophysiology
Fifty-six young (postnatal days 20 -30) Wistar rats were decapitated, and 400 m thick coronal slices were prepared from their primary motor cortices. Slices were placed in a recording chamber and were perfused continuously with oxygenated artificial cerebrospinal fluid (ACSF) at 34°C. Bipolar stainless-steel microelectrodes were used to stimulate the layer II/III horizontal pathways. The stimulus intensity was adjusted between 20 and 70 A to evoke the half-maximum response. Glass micropipettes used for recordings were filled with ACSF and broken off so that the impedance was between 1.0 and 1.5 M⍀. The recordings were carried out at 300 -500 m from the stimulation.
Application of peptides
DAMGO or End-2 was applied either alone (5ϫ10 Ϫ5 M) or in a mixture with A␤1-42 at a molar ratio of 5:1. A␤1-42 was used alone in a concentration of 10 Ϫ5 M. Fifteen microliters of solution were applied in the close vicinity of the recording electrode with a Hamilton syringe equipped with a micromanipulator. The signals were amplified (SEC-LX05, npi), filtered (1-3 kHz), acquired at a 10 kHz sampling rate on a pClamp8 system and Digidata 1320 A/D board (Axon Instruments), and analyzed off-line with Origin 6.0 software (Microcal Software). The averaged amplitude (nϭ4) of the initial negative component of the field excitatory postsynaptic potentials (fEPSPs) evoked by stimuli was used as a measure of the population excitatory synaptic current.
In vivo electrophysiology
Extracellular single-unit recordings were made in 41 chloral hydrate-anesthetized (4 g/kg initial dose, ip, supplemental doses as required) male Wistar rats weighing 300 -360 g. The head of the animal was mounted in a stereotactic frame, the skull was opened above the hippocampus (antero-posterior: Ϫ2.8 to Ϫ3.8 from bregma; lateral: 2 mm on either side from
100 mM sodium acetate) ejection at Ϫ2 A for 20 min followed by conventional histology using neutral red contrastaining.
Extracellular recordings and iontophoresis
Single unit activity was extracellularly recorded by means of a low impedance (Ͻ1 M⍀) 7 m carbon fiber-containing microelectrode (Kation Scientific, Minneapolis, MN) from the hippocampus between the depths of 2-3 mM. Drugs were delivered from the surrounding outer barrels. The action potentials were amplified, filtered (ExAmp-20K, Kation Scientific; ref 35) , and monitored with an oscilloscope. A window discriminator was used for discriminating the spikes. The amplified signals were sampled and digitalized at 50 kHz frequency. The number of action potentials per second was counted by the computer, and peristimulus time histograms were calculated, displayed in line, and digitally stored for off-line analysis. Iontophoretic drug delivery and collection of experimental data were performed by a multifunction instrument control and data acquisition board (National Instruments PCI-1200) placed in a computer along with Union-36 iontophoretic pumps (Kation Scientific).
The following solutions were ejected: 1) 100 mM NMDA Na (Sigma-Aldrich, Budapest, Hungary) in 100 mM NaCl (pH 8.0); 2) 5 ϫ 10 Ϫ5 M A␤1-42; 3) 2.5 ϫ 10 Ϫ4 M DAMGO/ End-2 dissolved in saline (pH 6.4); and 4) a mixture containing A␤1-42 (5ϫ10 Ϫ5 M) and DAMGO/End-2 (2.5ϫ10 Ϫ4 M) stored for 24 h at 4°C. To lessen the degree of aggregation, the A␤1-42 and the mixture solutions were sonicated (Merck Eurolab 120 W apparatus) for 15 min before use.
Neurons were excited by repetitive iontophoresis of NMDA at 1 min intervals for 5 s by applying negative iontophoretic currents ranging from 11 to 100 nA, and the ejection current was selected so that the maximum firing rate fell between 30 and 80 spikes/s. Retaining current of the opposite direction in the range 2-21 nA was used. The peristimulus time histograms of the neurons were recorded. After establishment of a stable control (at least 4 successive peaks), the solution to be examined was ejected: DAMGO/End-2 containing solution for 3 min at ϩ100 nA; A␤1-42 and the mixtures for 1 min at Ϫ0.5 A.
Data analysis
The results of the MTT assay were analyzed by using ANOVA with post hoc Bonferroni test (PϽ0.01). For in vitro electrophysiological studies, statistical significance was determined by means of Student's t test. In all cases, statistical significance was set at P Յ 0.05. Statistical evaluations of the in vivo results were performed by using the total number of spikes evoked during each epoch of excitation by iontophoretic application of the excitatory amino acid NMDA. The background neuronal discharge was calculated by averaging a 15 s period of ongoing activity preceding each epoch of excitation, and this value was subtracted from all evoked responses. The total spike number during each epoch of excitation was calculated and expressed as a percentage of the mean (Ϯse) and compared statistically with the data obtained after A␤1-42 application by using one-way ANOVA (with the Bonferroni test for post hoc analysis). A P value of at least 0.05 was considered significant in all cases.
RESULTS
TEM
The aggregation process of A␤1-42 was followed with TEM during 5 days. The putative ␤-sheet-breaker effect of End-2 was also studied coincubating A␤1-42 with the tetrapeptide. A few protofibrils and spherical oligomers could be observed at 0 h in both solutions (Fig. 1, A and  B, top) . After 1 day of incubation, both samples contained long, mature, smooth amyloid fibrils emanating from the seeding centers without any observable difference between the two time-matched different samples (Fig. 1, A and B, middle) . Although the concentration of fibrils increased further after a 5 day incubation period, the End-2 containing solution resembled the control one: the tetrapeptide did not affect the fibrillogenesis of A␤1-42 (Fig. 1, A and B, bottom) .
QLS measurements
QLS measurements were performed to characterize the aggregation altering effect of End-2 compared with the reference peptide LPFFD. Figure 2 represents the distribution curves of R h values over the scattered intensity in these experiments. According to our results, A␤1-42 can be characterized with a bimodal curve having the maxima at R h ϭ 91 and 684 nm. LPFFD showed the expected BSB effect on the aggregation course: beside the two maxima falling into either the protofibrillar (81 nm) or the fibrillar size range (549 nm), a new peak appeared representing the small oligomers (R h ϭ20 nm). The ratio of the integrated intensities is 1:3.9:13.2 (oligomers/protofibrils/fibrils, respectively). Because the scattering intensity of a particle is proportional to the sixth power of its diameter, it can be assumed that the sample contains predominantly small oligomers together with the fibrillar aggregates. On the contrary, End-2 was not capable of changing the aggregation profile of A␤1-42 considerably; in the case of coincubation with End-2, its intensity distribution curve possessed the same bimodal characteristic (maxima at 157 and 759 nm) as without the tetrapeptide in the control sample.
Radioligand binding studies
To demonstrate the actual binding of End-2 to A␤1-42, we have used a radioligand binding assay with [ 3 H]-labeled End-2. The amount of [ 3 H]End-2 bound to aggregated A␤1-42 was decreased in a concentrationdependent manner by the addition of unlabeled End-2, indicating that the binding was competitive. However, the steady-state condition was not reached even after 7 days of incubation. The possible cause for that could be the ongoing fibrillogenesis of A␤1-42.
CD measurements
The CD spectra of A␤1-42 alone and in the presence of End-2 at 1:1 M ratio in the function of aging time are shown in Fig. 3, B-D. The shape of the CD curve of A␤1-42 (Fig. 3B) at t ϭ 0 time reflects the mixture of various conformations: the broad negative band is contributed by the n* transition (Ϸ215 nm) of ␤-sheet conformation and the class C spectrum of ␤-turns type I/III or 3 10 helix (36). The positive band, which is expected to appear below 200 nm in the case of both ␤-sheet (strand) or ␤-turn structures, is suppressed by the intensive negative band of the unordered (random coil) conformation. Indeed, at t ϭ 0, the low (negative) values of the spectrum here are indicative of the presence of a considerable amount of unordered secondary structures. As the peptide ages, a gradual spectral change can be observed: the intensity of both the positive and negative band increases reaching their maximal values after 48 h incubation. This reflects a conformational transition from a randomcoil-rich form to a ␤-sheet-rich form. In the presence of End-2, the shape of the spectrum measured immediately after dissolution (at 0 h) is different ( Fig. 3C) : the appearance of a positive band at Ϸ200 nm is due to the positive band of End-2 in this spectral range. The strong interaction between A␤1-42 and End-2 (at 0 h) is reflected by the considerable difference between the measured spectrum of the complex and the sum spectrum of the free A␤1-42 and free End-2 (Fig. 3D) 48 h ). The CD spectra of the mixture of A␤1-42 and End-2 after standing for 1-3 h are shown in Fig. 3C : the intensity of the positive band at Ϸ200 nm is increasing, reflecting a higher amount of ␤-sheet content. Practically no further intensity increase can be observed between 3 and 24 h. A typical ␤-sheet spectrum appears only after 48 h incubation; all the other spectra reflect the presence of a small amount turn conformation in addition to ␤-sheet.
MTT cell viability assay
To elucidate the putative neuroprotective action of End-2 against A␤, MTT assay was used. Both End-2 and DAMGO were applied in 1, 10, 100 and 200 M either alone or in a mixture with 10 Ϫ5 M A␤1-42. Application of 10 Ϫ5 M A␤1-42 resulted in a decrease of cell viability. Reduction of MTT into formazan in the SH-SY5Y cell line decreased to 58 Ϯ 8% (nϭ21), as described previously (17, 37) . DAMGO, applied in gradually increasing concentration, was unable to interfere with A␤1-42 induced decrease of MTT reduction. In contrast, End-2 could significantly attenuate the inhibition of MTT reduction of A␤1-42 in a dosedependent manner. The effect was significant when the tetrapeptide was applied in 100 and in 200 M concentration with 10 Ϫ5 M A␤1-42 (Fig. 4, 77Ϯ7 and 79Ϯ10%, respectively, PϽ0.01, nϭ21). DAMGO and End-2 did not affect cell viability alone at the concentrations used (data not shown).
In vitro electrophysiology: fEPSP recordings
The amplitude of the initial negative component of the fEPSP evoked by stimuli applied through horizontally displaced electrodes in layers II/III was recorded. A␤1-42 at a concentration of 10 Ϫ5 M decreased the amplitude of the fEPSPs to 58.9 Ϯ 10% (PϽ0.05, nϭ15; Fig. 3 ). Application of End-2 in a concentration of 5 ϫ 10 Ϫ5 M did not change the amplitudes (100.3Ϯ17.6%, nϭ13). The A␤1-42 and End-2 (1:5 M ratio) mixture application resulted only in a slight decrease of the fEPSP amplitude: the value of 91.7 Ϯ 11.4% (nϭ14) did not differ significantly from the control concentration; 5 ϫ 10 Ϫ5 M DAMGO did not alter the measured fEPSPs (92.8Ϯ16%, nϭ6). In contrast, application of A␤1-42 and DAMGO mixture in 1:5 M ratio resulted in signif- icant fEPSP amplitude attenuation (57Ϯ14%, nϭ8, PϽ0.05).
In vivo iontophoresis and single-unit activity: modulation of the NMDA-evoked neuronal firing
Effects of End-2 and DAMGO
End-2 alone was ejected for 3 min after establishing a stable evoked neuronal firing (control). The NMDAevoked responses increased up to a maximum of 162 Ϯ 14% (nϭ9, PϽ0.05), which proved to be significant compared to the control response concentration (Fig.   4B and Fig. 5) . Response enhancement lasted for 18 -20 min, and then the concentration of triggered neuronal firing returned to control concentration. DAMGO application for 3 min resulted in similar significant response enhancement to 167 Ϯ 5% (nϭ5, PϽ0.05). However, the evoked responses did not return to the control concentration within the time frame of the experiment, and the enhancement proved to be long lasting. Application of the vehicle had no effect on the neuronal firing (nϭ6, data not shown).
Effect of aggregated A␤1-42
After A␤1-42 application, the NMDA-evoked responses (frequency of spikes) significantly enhanced (Fig. 4A) to 269 Ϯ 16% (nϭ14, PϽ0.05) as compared with the preA␤1-42 control. The enhancement gradually increased up to a maximum value and did not return to the control concentration within the 40-min time frame of the experiments, as described by Molnar et al. (16) and Szegedi et al. (17) . In contrast, iontophoresis of the saline without peptide caused no change in the baseline activity or in the NMDA-evoked firing rate (nϭ6, data not shown).
Effect of mixtures containing A␤1-42 and End-2 or A␤1-42 and DAMGO
The peptide mixtures were administered iontophoretically for 1 min at Ϫ0.5 A. In that way, only the negatively charged A␤1-42 was ejected; End-2/ DAMGO could not leave the micropipette, unless absorbed on the surface of different A␤1-42 assemblies. Application of the End-2 and A␤1-42 mixture did not result in enhancement of the NMDA responses (Fig.  4D) : the concentration of neuronal firing remained at 115 Ϯ 21% (nϭ6; Fig. 5 ). In contrast, ejection of the DAMGO and A␤1-42 containing solution enhanced NMDA-evoked firing. The maximum response to 269 Ϯ 37% remained, and it did not return to control concentration (nϭ6, PϽ0.05). 
Coiontophoresis of A␤1-42 and End-2 or A␤1-42 and DAMGO
To elucidate the protective mechanism of End-2 against the effect of A␤1-42, coiontophoretic administration was used. End-2 and DAMGO were ejected right before A␤1-42 application with the same current and time frame as described above to ensure the effective concentration in the close vicinity of the neuron. In that way, MORs will be activated, and the drugs will not exert their putative protective effect on the surface of aggregated A␤1-42 species. Immediately after ejection of End-2, A␤1-42 was applied. The maximum NMDAevoked response reached 348 Ϯ 65%, and the enhancement remained during the measurements (nϭ7, PϽ0.05; Figs. 4C and 5). Coiontophoresis of DAMGO with A␤1-42 resulted in similar response enhancement. The maximum evoked response was 238 Ϯ 37%, and the effect did not diminish during the time frame of the experiment (nϭ6, PϽ0.05).
DISCUSSION
Our results show that End-2 possesses protective properties against A␤1-42 induced attenuation of cell redox activity and neuromodulation in vitro and in vivo. End-2 was able to attenuate the decrease of MTT reduction by ␤-amyloid in an in vitro cell viability test in a dosedependent manner (Fig. 4) . Inhibition of MTT reduction by A␤ is not an indicator of actual cell death (38, 39) . Although the decrease of cellular redox activity after A␤ application is not due to massive cell loss, the MTT test is a widely used assay for indicating the overall metabolic rate of cultured neurons. Synaptic changes emerge well before actual neuronal death in early AD (40 -42) . Because inhibition of MTT reduction by A␤ is supposed to be due to changes in membrane properties (43) and exocytosis (44) , which can significantly affect normal synaptic working, the MTT test with A␤ may be exploited as an indicator of possible synaptotoxicity. In accord to this phenomenon, End-2 offered protection against the fEPSP attenuation caused by A␤1-42 in in vitro brain slice experiments (Fig. 5) . The amyloidinduced enhancements of NMDA-evoked responses were also diminished by End-2 in vivo (Figs. 6 and 7) . These protective effects were not mediated through the activation of MOR, because DAMGO, a synthetic MOR agonist was not able to attenuate the A␤1-42 mediated effects. Results of the two kinds of in vivo iontophoretic experiments ("mixture" and "coiontophoresis") provided additional evidence that the activation of MORs does not yield protection against A␤1-42. Coiontophoretic application of A␤1-42 with either End-2 or DAMGO resulted in NMDA-induced response enhancement, similar to the effect of ␤-amyloid. However, when A␤1-42 was preincubated with End-2, no ␤-amyloid induced enhancement could be measured (Figs. 6  and 7) . In coiontophoretic experiments, the ejection of MOR agonists preceded A␤1-42 application to activate the -receptors. In contrast, at application of the mixture solutions, the pH values and the ejection polarities were chosen in that way that only A␤1-42 and the possibly bound End-2 and DAMGO could leave the capillary. Under these conditions, presumably no significant MOR activation occurred due to the ejection of the mixtures.
End-2 does not arrest fibril formation or disassemble preformed aggregates, as revealed by TEM and QLS measurements ( Figs. 1 and 2) . The particle size distribution of End-2 incubated A␤1-42 resembles that of A␤1-42 alone after 48 h, indicating that there was no interference with aggregation kinetics. In contrast, BSB compounds, such as LPFFD, a pentapeptide that is capable of arresting and reversing fibril formation (25, 45) , shifted the particle size distribution toward small aggregates and dimers (Fig. 2, and, (Fig. 3) . In addition, data from the CD measurements suggest that A␤1-42 and End-2 formed a complex in the initial state of the aggregation process.
It is controversial whether all stages of aggregated A␤1-42 exert action leading to neural compromise. Previous studies provided evidence that the small-size aggregates (protofibrils, oligomers) are likely to affect neurons (46, 47) , and fibrillar species may trigger glial cells to produce toxic mediators (e.g, 48, 49) . The applied A␤1-42 in our biological measurements contained a wide range of different sized aggregated particles; however, End-2 was capable of inhibiting their biological effects. Wogulis et al. (38) suggested that the process of fibril formation causes the neuronal damage. Fibrillogenesis was evident under our experimental conditions; nevertheless, A␤1-42 induced changes were diminished in the presence of End-2; therefore, the tetrapeptide may have protected against this possible phenomenon as well.
Recent reports indicated that not all types of aggregated assemblies are neurotoxic (38, 50) or different conformational states may have different biological activity (51) . End-2 might be bound to the biological harmful assemblies, transforming their conformation into a harmless structure, or by inhibiting the interaction between cells and A␤ aggregates. By doing so, the tetrapeptide may offer protection against assemblies of different aggregation states. The novel mechanism of protection prones the tetrapeptide to be a very promising candidate for future research in the combat against AD. A recent report (52) underlies the risk of approaches aimed at "bustering" or inhibiting the formation of A␤ fibrils. Because oligomers are supposed to have greater inherent toxicity than fibrils, arresting or reversing fibril formation may exaggerate brain damage in AD.
Being an endogenous substance, End-2 might play a role in the actual AD progression and possibly assent to the area selective cell loss seen in the disease. CNS areas with high End-2 content were found to be unaffected by A␤-induced damage (29 -31) . Those areas that suffer cell loss in AD, including the hippocampal formation and neocortex, show no or little End-2 like immunoreactivity. Only a few endogenous molecules have been reported or suggested to have protective effect against ␤-amyloid (i.e., taurine (53) and kynurenic acid (54)), which target the excitotoxic imbalance either by GABA A receptor activation or by NMDA receptor inhibition. Shifting the net concentration of neuronal excitability toward inhibition attenuates Ca 2ϩ entry. Decreased intracellular Ca 2ϩ concentration provides less probability of apoptotic cascade initiation. Another endogenous compound, melatonin, has a more complex neuroprotective mechanism. In addition to its antioxidant properties, it also binds to the GABA A receptor (53) . Additionally, melatonin blocks fibrillogenesis of A␤1-42 in vitro (24) .
The effect of MOR activation on the in vivo NMDAevoked neuronal firing indicated that the action potentials of pyramidal cells were recorded (Figs. 6 and 7) . The distribution of MOR in the hippocampus displays cell type specificity: only the GABA-ergic interneurons express this type of inhibitory, metabotropic receptor (55, 56) . Therefore, excitation after End-2 and DAMGO ejection indicates a disinhibitory mechanism (57): -receptor bearing interneurons might be inhibited by agonists, resulting in an attenuation of the inhibitory input to the pyramidal cells, increasing their excitability.
Approaches aimed to increase End-2 concentration in the brain presumably would not offer rational treatment of AD patients. The activation of MORs increases the net excitability in the CA1 region and may result in focal epileptic seizures (57) . Consequently, in the treatment of AD, the sequence of End-2 is what may be exploited as a lead sequence for development of peptidomimetic drugs that will not activate -opioid receptors. 
